Extended-Release Calcifediol for SHPT Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, particularly those with Vitamin D insufficiency, often fail to maintain serum total 25-hydroxyvitamin D levels above 30 ng/mL, leading to inadequate control of elevated parathyroid hormone (PTH) and progression of bone disease.

Innovation Solution

Administering extended-release 25-hydroxyvitamin D formulations, such as calcifediol, to maintain serum total 25-hydroxyvitamin D levels above 50 ng/mL, thereby reducing PTH levels and halting or reversing SHPT progression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immediate release vitamin D formulations are administered, then vitamin D is delivered to the patient, but serum 25-hydroxyvitamin D levels cannot be maintained above 50 ng/mL

Engineering Contradiction:

Improveability to maintain serum 25-hydroxyvitamin D levels above 50 ng/mLVSAvoidduration of vitamin D effect

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent transitions from static immediate release formulations to dynamic extended release formulations that adaptively deliver vitamin D over time. The extended release mechanism adjusts the release rate to maintain serum levels above 50 ng/mL, resolving the contradiction between reliability of maintaining therapeutic levels and duration of action.

Inventive Principle:

Principle #15Dynamics

Solution Approach 2:

The patent changes the release parameter of vitamin D from immediate to extended release, fundamentally altering the pharmacokinetic profile. This parameter change enables sustained serum 25-hydroxyvitamin D levels above 50 ng/mL, directly resolving the contradiction between maintaining reliable therapeutic levels and extending duration of action.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If extended release 25-hydroxyvitamin D formulations are administered, then PTH levels are reduced by at least 30%, but formulation complexity increases

Engineering Contradiction:

Improvecontrol of PTH levelsVSAvoidformulation complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs parameter changes in the formulation design, transitioning to extended release mechanisms that control the release kinetics of 25-hydroxyvitamin D. This enables reliable PTH level control (reduction by at least 30%) while managing formulation complexity through established extended release technologies.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If higher serum 25-hydroxyvitamin D levels are targeted, then SHPT progression is halted or reversed, but risk of adverse effects increases

Engineering Contradiction:

Improvecontrol of SHPT progressionVSAvoidadverse effects from high vitamin D levels

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses dynamic extended release formulations that progressively build and maintain serum 25-hydroxyvitamin D levels above 50 ng/mL. This dynamic approach allows the body to adapt to higher vitamin D levels over time, halting or reversing SHPT progression while minimizing adverse effects through controlled, sustained delivery rather than acute high doses.

Inventive Principle:

Principle #15Dynamics

Data Source

PatentUS20220226351A1Method of Controlling Progression of Hyperparathyroidism, And Compositions for Use Therein

Publication Date: 2022.07.21 EIRGEN PHARMA LTD

AI summary

Methods and compositions for controlling hyperparathyroidism are disclosed.